Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators

Mohamed L. Sorror

Blood (2023) 141 (18): 2173–2186.

https://doi.org/10.1182/blood.2022017999

Published: 2023

Journal Articles

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Blood (2023) 141 (3): 295–308.

https://doi.org/10.1182/blood.2022016916

Published: 2023

Includes: Supplemental data

Journal Articles

Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms

Blood (2022) 140 (Supplement 1): 5254–5257.

https://doi.org/10.1182/blood-2022-165437

Published: 2022

Journal Articles

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Blood (2022) 139 (26): 3722–3731.

https://doi.org/10.1182/blood.2021014497

Published: 2022

Includes: Supplemental data

Journal Articles

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Blood (2021) 138 (5): 387–400.

https://doi.org/10.1182/blood.2020008812

Published: 2021

Includes: Supplemental data

Journal Articles

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

Mary-Elizabeth M. Percival, MD, Megan Othus, PhD, Sarah Mirahsani, Kelda M. Gardner, PA-C, Carole M. Shaw, BA, Anna B. Halpern, MD, Paul C. Hendrie, MD PhD, Pamela S. Becker, MD PhD, Mohamed L. Sorror, MD MSc, Roland B. Walter, MD PhD MS, Elihu H. Estey, MD

Blood (2019) 134 (Supplement_1): 3824.

https://doi.org/10.1182/blood-2019-130834

Published: 2019

Journal Articles

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Monica S. Thakar, Larisa Broglie, Brent Logan, Andrew Artz, Nancy Bunin, Lauri M. Burroughs, Caitrin Fretham, David A. Jacobsohn, Alison W. Loren, Joanne Kurtzberg, Caridad A. Martinez, Shin Mineishi, Adam S. Nelson, Ann Woolfrey, Marcelo C. Pasquini, Mohamed L. Sorror

Blood (2019) 133 (7): 754–762.

https://doi.org/10.1182/blood-2018-09-876284

Published: 2019

Includes: Supplemental data

Journal Articles

Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model

Ylinne Lynch, MD, Shirali Agarwal, MD, Matthew Modes, MD MPP, Matthew Triplette, MD MPH, Masumi Ueda, MD, Barry E. Storer, PhD, Mary-Elizabeth M. Percival, MD MS, Pamela S. Becker, MD, Brenda M. Sandmaier, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD, Mohamed L. Sorror, MD MSc

Blood (2018) 132 (Supplement 1): 3986.

https://doi.org/10.1182/blood-2018-99-115419

Published: 2018

Journal Articles

Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia

Sarah Elsayed, MD, Barry E. Storer, PhD, Bruno C. Medeiros, MD, Mona Ahmed Asslan, MSc, Ylinne Lynch, MD, Jennifer E. Nyland, PhD, Pamela S. Becker, MD, Mary-Elizabeth M. Percival, MD, Elihu H. Estey, MD, Mohamed L. Sorror, MD MSc

Blood (2018) 132 (Supplement 1): 3992.

https://doi.org/10.1182/blood-2018-99-117415

Published: 2018

Journal Articles

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study

Blood (2018) 132 (Supplement 1): 1388.

https://doi.org/10.1182/blood-2018-99-112672

Published: 2018

Journal Articles

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

Blood (2018) 132 (Supplement 1): 207.

https://doi.org/10.1182/blood-2018-99-113094

Published: 2018

Journal Articles

Clinical Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients with Richter's Transformation (RT) to Aggressive Non-Hodgkin Lymphoma (aNHL): a Single-Institution Experience

Mazyar Shadman, MDMPH, Sirin Khajavian, MD, Andrew J. Cowan, MD, Andrei R. Shustov, MD, Brian G Till, MD, Ryan D. Cassaday, MD, Mohamed L Sorror, MD MSc, Leona Holmberg, MD PhD, E Houston Warren, MDPhD, Lori Soma, MD, Edward N. Libby, III, MD, David G. Maloney, MD PhD, Ajay K. Gopal, MD, Oliver W. Press, MD PhD, Stephen D. Smith, MD

Blood (2017) 130 (Supplement 1): 4308.

https://doi.org/10.1182/blood.V130.Suppl_1.4308.4308

Published: 2017

Journal Articles

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

Blood (2017) 130 (9): 1156–1164.

https://doi.org/10.1182/blood-2017-03-772368

Published: 2017

Includes: Supplemental data

Journal Articles

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality

Joshua A. Hill, Bryan T. Mayer, Hu Xie, Wendy M. Leisenring, Meei-Li Huang, Terry Stevens-Ayers, Filippo Milano, Colleen Delaney, Mohamed L. Sorror, Brenda M. Sandmaier, Garrett Nichols, Danielle M. Zerr, Keith R. Jerome, Joshua T. Schiffer, Michael Boeckh

Blood (2017) 129 (16): 2316–2325.

https://doi.org/10.1182/blood-2016-10-748426

Published: 2017

Includes: Supplemental data

Journal Articles

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models

Blood (2016) 128 (22): 216.

https://doi.org/10.1182/blood.V128.22.216.216

Published: 2016

Journal Articles

Pre-Transplant Expressions of Micrornas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD MS, Theodore A Gooley, PhD, Kirsteen Maclean, PhD, Shamali Roy, PhD, Jesse Hubbard, Mario Marcondes, MD PhD, Beverly Torok-Storb, PhD, Tewari Muneesh, MD PhD

Blood (2015) 126 (23): 385.

https://doi.org/10.1182/blood.V126.23.385.385

Published: 2015

Journal Articles

Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality

Mohamed L Sorror, MD MSc, Barry E. Storer, PhD, Mahmoud Elsawy, MD MSc, Amir T Fathi, MD, Andrew Brunner, MD, Aaron T. Gerds, MD MS, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD, Bruno C. Medeiros, MD, Paul Shami, MD, Esteban Peña, MD, Shylo Wardyn, MS, Jennifer Whitten, MPH, Hannah Frenkel, BS, Jeannine McCune, PharmD, Stephanie J. Lee, MD MPH, Elihu H. Estey, MD

Blood (2015) 126 (23): 532.

https://doi.org/10.1182/blood.V126.23.532.532

Published: 2015

Journal Articles

Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study

Jennifer E. Vaughn, MD MSPH, Barry E. Storer, PhD, Philippe Armand, MD PhD, Roberto Raimondi, MD, Christopher J Gibson, MD, Alessandro Rambaldi, MD, Fabio Ciceri, MD, Rosi Oneto, MD, Benedetto Bruno, MD PhD, Paul J. Martin, MD, Brenda M. Sandmaier, MD, Rainer F. Storb, MD, Mohamed L. Sorror, MD MSc

Blood (2014) 124 (21): 421.

https://doi.org/10.1182/blood.V124.21.421.421

Published: 2014

Journal Articles

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Mahmoud Elsawy, MD MSc, Barry E. Storer, PhD, Brenda M. Sandmaier, MD, Colleen Delaney, MD MSC, Frederick R. Appelbaum, MD, Ann E Woolfrey, MD, David G Maloney, MDPhD, Rainer F. Storb, MD, Mohamed L. Sorror, MD MSc

Blood (2014) 124 (21): 2583.

https://doi.org/10.1182/blood.V124.21.2583.2583

Published: 2014

Journal Articles

Comorbidity Index in the Context of Cord Blood Transplantation: An Accurate Predictor of Treatment Related Mortality?

David C. Oliver, Filippo Milano, MD PhD, Colleen Delaney, MD MSC, Mohamed L. Sorror, MD MSc, Rachel B. Salit, MD

Blood (2014) 124 (21): 1205.

https://doi.org/10.1182/blood.V124.21.1205.1205

Published: 2014

NARROW

The use of prognostic models in allogeneic transplants: a perspective guide for clinicians and investigators

An 8-year pragmatic observation evaluation of the benefits of allogeneic HCT in older and medically infirm patients with AML

Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms

Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL

Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia

Frequency, and Effect on Survival, of Ineligibility for Clinical Trials in Newly Diagnosed Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases

Predictors of 90-Day Mortality after Admission to Intensive Care Unit (ICU) in Patients with Acute Myeloid Leukemia (AML): Application of a Novel, Recently Validated AML-Specific Risk Model

Augmentation of the Acute Myeloid Leukemia-Composite Model (AML-CM) with Performance Status and Secondary Leukemia

Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study

Survival Differences Among Patients (pts) with Acute Myeloid Leukemia (AML) Treated with Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Non-HCT Therapies: A Large Real-Time Multi-Center Prospective Longitudinal Observational Study

Clinical Outcomes of Chronic Lymphocytic Leukemia (CLL) Patients with Richter's Transformation (RT) to Aggressive Non-Hodgkin Lymphoma (aNHL): a Single-Institution Experience

Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States

The cumulative burden of double-stranded DNA virus detection after allogeneic HCT is associated with increased mortality

Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models

Pre-Transplant Expressions of Micrornas Are Associated with Both Comorbidity Burden and Mortality Risks in Patients (Pts) with Acute Leukemia (AL) in Complete Remission (CR) Given Allogeneic Hematopoietic Cell Transplantation (HCT)

Impact of Comorbidities at Diagnosis of Acute Myeloid Leukemia on One-Year Mortality

Pre-Transplant Ferritin, Albumin and Platelet Count Add Prognostic Information to Comorbidities for Allogeneic Hematopoietic Cell Transplantation (HCT) Outcomes: A Multi-Center Discovery-Validation Study

Role of Comorbidities in Prognostic Evaluation of Outcomes Following Allogeneic Hematopoietic Cell Transplantation (HCT) from HLA-Mismatched (MM) and Umbilical Cord Blood (UCB) Donor Grafts

Comorbidity Index in the Context of Cord Blood Transplantation: An Accurate Predictor of Treatment Related Mortality?

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only